共 50 条
- [21] Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer[J]. CANCER RESEARCH, 2021, 81 (04)Wolf, Denise M.Yau, ChristinaBrown-Swigart, LamornaO'Grady, NickHirst, GillianSit, LauraAsare, SmitaBerry, DonEsserman, LauraHan, HyoPusztai, Lajosvan 't Veer, Laura
- [22] Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Thomas, AlexandraWolf, Denise M.Balassanian, RonaldChen, Yunn-YiYe, JuliaVohra, PoonamGulbahce, Evin H.Borowsky, Alexander D.Swigart, Lamorna BrownHirst, Gillian L.Venters, SaraNanda, RitaShatsky, Rebecca ArielleD'Agostino, Ralph, Jr.Mukhtar, Rita A.Hatcher, SarahYau, ChristinaDeMichele, Angelavan't Veer, LauraEsserman, Laura
- [23] Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL[J]. CANCER RESEARCH, 2022, 82 (04)Bareng, Teffany JoyGibbs, Jessica E.Onishi, NatsukoNewitt, David C.LeStage, BarbaraHylton, Nola M.
- [24] I-SPY 2 may change how clinical trials are conducted[J]. CANCER, 2013, 119 (11) : 1925 - 1927Printz, Carrie
- [25] I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2-breast cancer and molecular good-prognosis gene signature.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Haddad, Tufia C.Shah, Mamta D.Symmans, William FraserHylton, NolaYau, ChristinaLyandres, JuliaMelisko, Michelle E.Forero, AndresAlbain, Kathy S.Kaplan, Henry G.Viscusi, Rebecca KleinBerry, Donald A.Esserman, LauraChien, Amy Jo
- [26] Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial[J]. CANCER RESEARCH, 2022, 82 (04)Kyalwazi, BeverlyYau, ChristinaOlopade, OlufunmilayoChien, A. JoWallace, AnneForero-Torres, AndresPusztai, LajosEllis, ErinAlbain, KathyBlaes, AnneHaley, BarbaraBoughey, JudyElias, AnthonyClark, AmyIsaacs, ClaudineNanda, RitaHan, HyoYung, RachelTripathy, DebuEdmiston, KristenViscusi, RebeccaNorthfelt, DonaldKhan, QamarSanil, AshishBerry, ScottAsare, SmitaWilson, AmyHirst, GillianHylton, NolaMelisko, MichellePerlmutter, JaneRugo, HopeSymmans, Fraservan 't Veer, LauraBerry, DonaldEsserman, Laura
- [27] Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL[J]. npj Breast Cancer, 6Wen LiDavid C. NewittJessica GibbsLisa J. WilmesElla F. JonesVignesh A. ArasuFredrik StrandNatsuko OnishiAlex Anh-Tu NguyenJohn KornakBonnie N. JoeElissa R. PriceHaydee Ojeda-FournierMohammad EghtedariKathryn W. ZamoraStefanie A. WoodardHeidi UmphreyWanda BernreuterMichael NelsonAn Ly ChurchPatrick BolanTheresa KuritzaKathleen WardKevin MorleyDulcy WolvertonKelly FountainDan Lopez-PaniaguaLara HardestyKathy BrandtElizabeth S. McDonaldMark RosenDespina KontosHiroyuki AbeDeepa ShethErin P. CraneCharlotte DillisPulin ShethLinda Hovanessian-LarsenDae Hee BangBruce PorterKaren Y. OhNeda JafarianAlina TudoricaBethany L. NiellJennifer DrukteinisMary S. NewellMichael A. CohenMarina GiurescuElise BermanConstance Lehman
- [28] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL[J]. CANCER RESEARCH, 2014, 74 (19)Park, John W.Liu, Minetta C.Yee, DouglasDeMichele, Angelavan't Veer, LauraHylton, NolaSymmans, FraserBuxton, Meredith B.Chien, A. JoWallace, AmyMelisko, MichelleSchwab, RichardBoughey, JudyTripathy, DebashishKaplan, HankNanda, RitaChui, StephenAlbain, Kathy S.Moulder, StacyElias, AnthonyLang, Julie E.Edminston, KirstenNorthfelt, DonaldEuhus, DavidKhan, QamarLyandres, JuliaDavis, Sarah E.Yau, ChristinaSanil, AshishEsserman, Laura J.Berry, Donald A.
- [29] Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial[J]. CANCER RESEARCH, 2020, 80 (04)Li, WenOnishi, NatsukoNewitt, David C.Gibbs, JessicaWilmes, Lisa J.Jones, Ella F.Joe, Bonnie N.Sit, Laura S.Yau, ChristinaChien, A. JoPrice, ElissaAlbain, Kathy S.Kuritza, TheresaMorley, KevinBoughey, Judy C.Brandt, KathyChoudhery, SadiaClark, Amy S.Rosen, MarkMcDonald, Elizabeth S.Elias, Anthony D.Wolverton, DulcyFountain, KellyEuhus, David M.Han, Heather S.Niell, BethanyDrukteinis, JenniferLang, Julie E.Lu, JaniceMeisel, Jane L.Mitri, ZahaNanda, RitaNorthfelt, Donald W.Sanft, TaraStringer-Reasor, EricaViscusi, Rebecca K.Wallace, Anne M.Yee, DouglasYung, RachelAsare, Smita M.Melisko, Michelle E.Perlmutter, JaneRugo, Hope S.Schwab, RichardSymmans, W. Fraservan't Veer, Laura J.Berry, Donald A.DeMichele, AngelaAbe, HiroyukiSheth, Deepa
- [30] The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL[J]. CANCER RESEARCH, 2016, 76Albain, K. S.Leyland-Jones, B.Symmans, F.Paoloni, M.van't Veer, L.DeMichele, A.Buxton, M.Hylton, N.Yee, D.Clennell, J. LyandresYau, C.Sanil, A.Berry, D.Esserman, L.